Form 4: Quest Diagnostics SVP Sells Shares
Insider Transaction Report
Quest Diagnostics SVP Patrick Plewman exercised stock options and sold a portion of his common stock holdings under a pre-arranged 10b5-1 plan.
Summary
- Patrick Plewman, SVP for Diagnostic Services at Quest Diagnostics Inc. (DGX), engaged in transactions involving company common stock on August 6, 2025.
- He exercised 3,560 non-qualified stock options at an exercise price of $86.63 per share.
- Concurrently, he sold 3,560 shares of common stock at a price of $175.00 per share.
- Additionally, he sold an extra 1,975 shares of common stock at $175.00 per share.
- All reported transactions were executed under a Rule 10b5-1 sales plan.
- Following these transactions, Patrick Plewman beneficially owns 19,219 shares of Quest Diagnostics common stock, which includes exempt purchases from the company's stock purchase plan.
Sentiment
Score: 5
Explanation: Neutral. This is a routine insider transaction under a pre-arranged plan, not indicative of significant positive or negative company news.
Positives
- The transactions were executed under a Rule 10b5-1 plan, indicating pre-planned sales and not a reaction to new, non-public information.
- The exercise of options at $86.63 and subsequent sale at $175.00 indicates a significant profit for the insider on the exercised shares.
Negatives
- An insider sale, even if pre-planned, reduces the insider's direct ownership in the company.
Future Outlook
NA
Industry Context
NA
Stakeholder Impact
- Shareholders: Minor impact as it's a pre-planned insider sale, not necessarily signaling a change in company fundamentals.
Key Dates
| Date | Description |
|---|---|
| 02/18/2020 | First annual vesting installment of non-qualified stock options. |
| 02/18/2021 | Second annual vesting installment of non-qualified stock options. |
| 02/18/2022 | Final annual vesting installment of non-qualified stock options. |
| 08/06/2025 | Date of stock option exercise and common stock sales. |
| 08/08/2025 | Date of filing signature. |
Recommendation
holdThe filing details a routine insider transaction under a pre-arranged 10b5-1 plan, which is a common practice for executives to manage their equity holdings. It does not provide new fundamental information about Quest Diagnostics' business operations, financial performance, or strategic direction that would warrant a change in investment recommendation. The sale is a planned event and not indicative of a negative outlook on the company's future.
Keywords
Quest Diagnostics, DGX, Insider Trading, Form 4, Stock Option Exercise, Share Sale, 10b5-1 Plan, Patrick Plewman, Diagnostic Services
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.